Analysts’ Weekly Ratings Updates for Pieris Pharmaceuticals (PIRS)

Pieris Pharmaceuticals (NASDAQ: PIRS) recently received a number of ratings updates from brokerages and research firms:

  • 8/6/2019 – Pieris Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany. “
  • 8/1/2019 – Pieris Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock. They wrote, “Valuation and risks to price target achievement. We reiterate our Buy rating and price target of $7. Currently our valuation is based on the three lead assets at the company: (1) PRS-060 for asthma, which is partnered with AstraZeneca contributing 33% of our valuation; (2) PRS-343 for oncology, which currently contributes 39% of our valuation; and (3) PRS-080 for functional iron deficiency anemia contributing 28% of our valuation. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile.””
  • 7/30/2019 – Pieris Pharmaceuticals was downgraded by analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating. They now have a $5.00 price target on the stock.
  • 7/29/2019 – Pieris Pharmaceuticals was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 7/24/2019 – Pieris Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “strong-buy” rating to a “hold” rating. According to Zacks, “Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany. “
  • 7/11/2019 – Pieris Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $5.00 price target on the stock. According to Zacks, “Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany. “
  • 6/17/2019 – Pieris Pharmaceuticals was given a new $7.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.

Shares of NASDAQ:PIRS traded down $0.15 during midday trading on Thursday, hitting $4.90. The stock had a trading volume of 234,100 shares, compared to its average volume of 431,943. The company’s 50-day moving average price is $4.81 and its 200-day moving average price is $3.80. The company has a market capitalization of $244.00 million, a P/E ratio of -9.80 and a beta of 1.26. Pieris Pharmaceuticals Inc has a fifty-two week low of $2.39 and a fifty-two week high of $6.04.

Several large investors have recently modified their holdings of the company. Parametric Portfolio Associates LLC raised its position in shares of Pieris Pharmaceuticals by 25.4% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 21,177 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 4,290 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Pieris Pharmaceuticals by 1,074.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,874 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 5,374 shares in the last quarter. Strs Ohio raised its position in shares of Pieris Pharmaceuticals by 7.5% in the 2nd quarter. Strs Ohio now owns 112,900 shares of the biotechnology company’s stock valued at $530,000 after buying an additional 7,900 shares in the last quarter. Lindbrook Capital LLC acquired a new position in shares of Pieris Pharmaceuticals in the 2nd quarter valued at approximately $37,000. Finally, Clear Harbor Asset Management LLC acquired a new position in shares of Pieris Pharmaceuticals in the 2nd quarter valued at approximately $47,000. Institutional investors own 57.88% of the company’s stock.



Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Featured Article: Sell-Side Analysts

Receive News & Ratings for Pieris Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.